El largo y sinuoso camino en la comprensión de la insuficiencia cardíaca
DOI:
https://doi.org/10.47487/apcyccv.v1i3.79Palabras clave:
historia, insuficiencia cardiaca, TratamientoResumen
Un breve recorrido por la historia de la insuficiencia cardiaca.
Descargas
Referencias
Bianucci R, Loynes RD, Sutherland ML, et al. Forensic analysis reveals acute decompensation of chronic heart failure in a 3500-year-old Egyptian dignitary. J Forensic Sci 2016;61:1378–1381
Davis R, Hobbs F, Lip G. ABC of heart failure. History and epidemiology. BMJ. 2000;320:39-42
Ferrari R, Balla C, Fucili A. Heart failure: an historical perspective. European Heart Journal Supplements (2016) 18(Supplement G), G3–G10
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. doi:10.1056/NEJM198706043162301
CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9 -13.
Bertram Pitt, M.D., Faiez Zannad, M.D., Willem J. Remme, M.D. et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med 1999; 341:709-17
Bardy G, Lee K, Mark D, et al. Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure. N Engl J Med 2005; 352:225-37. DOI: 10.1056/NEJMoa043399
Abraham W, Fisher W, Smith A, et al. Cardiac Resynchronization in Chronic Heart Failure. N Engl J Med 2002; 346:1845-53. DOI: 10.1056/NEJMoa013168
McMurray J, Packer M, Desai A, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077
McMurray J, Solomon S, Inzucchi S, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303
Packer M, Anker S, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. DOI: 10.1056/NEJMoa2022190
Armstrong P, Pieske B, Anstrom K, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020; 382:1883-1893
DOI: 10.1056/NEJMoa1915928
Yusuf S, Pfeffer M, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81. DOI:10.1016/S0140-6736(03)14285-7
Saldarriaga-Giraldo C, Ramirez Ramos CF, Gallego C, et al. Falla cardiaca con fracción de eyección preservada: un problema de la cardiología contemporánea. APCyCCV [Internet]. 7 de julio de 2020 [citado 3 de septiembre de 2020];1(2):67-5. Disponible en: https://apcyccv.org.pe/index.php/apccc/article/view/53. https://doi.org/10.47487/apcyccv.v1i2.53
